Immunotherapy
Study identifies SLAMF6 as a self-activating brake on anti-cancer T cells, pointing to a new immunotherapy target
Raportoinut AI AI:n luoma kuva Faktatarkistettu
A research team led by Université de Montréal immunologist André Veillette reports that the immune receptor SLAMF6 can inhibit T cells by activating through interactions on the T cell surface itself, a mechanism the authors say could help explain why some patients fail to respond—or later stop responding—to checkpoint-based cancer immunotherapies. In the same study, the researchers describe monoclonal antibodies designed to block SLAMF6’s self-interaction, which boosted T-cell activity in laboratory tests and strengthened anti-tumor responses in mouse experiments.
A protein called NFIL3 has been identified as a key factor in reducing the long-term performance of CAR T cells used in cancer treatment. Researchers showed that disabling this protein allows the engineered cells to remain active longer and fight tumors more effectively in laboratory models.
Raportoinut AI Faktatarkistettu
Researchers at McGill University report a drug-based method to temporarily enhance natural killer (NK) cells—an immune cell type—by inhibiting two proteins, improving the cells’ ability to attack several aggressive cancers in preclinical experiments.
Scientists at KAIST in South Korea have developed a novel therapy that transforms a tumor's own immune cells into potent cancer fighters directly inside the body. By injecting lipid nanoparticles into tumors, the treatment reprograms macrophages to produce cancer-recognizing proteins, overcoming barriers in solid tumor treatment. Early animal studies show promising reductions in tumor growth.
Raportoinut AI
Researchers in Japan have uncovered how cancer cells use tiny vesicles to spread the immune-suppressing protein PD-L1, explaining why immunotherapy often fails. A protein called UBL3 directs this process, but common statins can disrupt it, potentially boosting treatment effectiveness. The findings, from patient samples and lab tests, suggest a simple way to improve outcomes for lung cancer patients.
Cold Spring Harbor Laboratory researchers report that engineered anti-uPAR CAR T cells cleared senescence-linked cells in mice, improving intestinal regeneration, reducing inflammation and strengthening gut barrier function. The approach also aided recovery from radiation-related intestinal injury and showed regenerative signals in experiments using human intestinal and colorectal cells, raising the possibility of future clinical trials.
Raportoinut AI
Researchers from MIT and Stanford University have developed multifunctional molecules called AbLecs to block sugar-based immune checkpoints on cancer cells. This approach aims to enhance immunotherapy by allowing immune cells to better target tumors. Early tests in cells and mice show promising results in boosting anti-tumor responses.
Stiffening cancer cells boosts car t-cell therapy in mice
20. maaliskuuta 2026 03.50Virus therapy enhances immune attack on glioblastoma
16. maaliskuuta 2026 16.23Engineered antibody shrinks tumors body-wide in early cancer trial
19. helmikuuta 2026 00.03Chinese team reports scalable way to generate large batches of engineered NK cells from cord-blood stem cells
6. helmikuuta 2026 21.16Study details “good” and “bad” regulatory T cells in colorectal cancer, pointing to more selective immunotherapy targets
20. tammikuuta 2026 03.55UBC researchers show how to reliably generate helper T cells from stem cells by tuning Notch signaling
16. tammikuuta 2026 22.24Vitamin A molecule helps cancer evade immune detection
15. tammikuuta 2026 14.16Northwestern antibody targets pancreatic cancer's immune evasion
11. tammikuuta 2026 01.35KAIST injection reprograms tumor macrophages into cancer fighters
9. tammikuuta 2026 12.54Scientists develop four-pronged antibodies to enhance immune response against cancer